Patrys is pleased to share its latest Newsletter, published June 2019.
Key highlights:
- Letter from our CEO
- Progress with PAT-DX1
- Overview of target indications
- Biologics M&A activity
- Development supported by grants
- Key conferences
- Profile: Dr Michael Stork